<?xml version="1.0" encoding="UTF-8" ?><!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
	"http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" >
<html><head><title>Side-by-side differences</title><link rel="stylesheet" type="text/css" href="/archive/history.css" /><link rel="stylesheet" type="text/css" href="/archive/sdiff.css" /><script type="text/javascript" src="/archive/common.js"></script><script type="text/javascript" src="/archive/sdiff.js"></script><style>table.sdiff div.sdl0 { margin-left: 0em; }
table.sdiff div.sdl1 { margin-left: 2em; }
table.sdiff div.sdl2 { margin-left: 4em; }
table.sdiff div.sdl3 { margin-left: 6em; }
table.sdiff div.sdl4 { margin-left: 8em; }
table.sdiff div.sdl5 { margin-left: 10em; }
table.sdiff div.sdl6 { margin-left: 12em; }
table.sdiff div.sdl7 { margin-left: 14em; }
table.sdiff div.sdl8 { margin-left: 16em; }
table.sdiff div.sdl9 { margin-left: 18em; }
table.sdiff div.sdl10 { margin-left: 20em; }
table.sdiff div.sdl11 { margin-left: 22em; }
table.sdiff div.sdl12 { margin-left: 24em; }
table.sdiff div.sdl13 { margin-left: 26em; }
table.sdiff div.sdl14 { margin-left: 28em; }
table.sdiff div.sdl15 { margin-left: 30em; }
table.sdiff div.sdl16 { margin-left: 32em; }
table.sdiff div.sdl17 { margin-left: 34em; }
table.sdiff div.sdl18 { margin-left: 36em; }
table.sdiff div.sdl19 { margin-left: 38em; }
</style></head><body class="sdiff">
<div class="navTop"><table class="navTopTriptych"><tr><td class="navTopTriptychL"><img src="/archive/ctgov_logo_ttl.gif" alt="ClinicalTrials.gov" width="360" height="47" /></td><td class="navTopTriptychC" style="background-image: url(/archive/ctgov_logo_ttm.gif)" /><td class="navTopTriptychR"><img src="/archive/ctgov_logo_ttr.gif" alt="Linking patients to medical research" width="314" height="47" /></td></tr></table></div>
<div id="sdiff-links" class="navLinks" /><div id="navLinks" class="navLinks"><a href="/archive/NCT00504075">&#8592; History of this study</a><a href="http://clinicaltrials.gov/show/NCT00504075">&#8593; Current version of this study</a></div><form><div id="sdiff-js-menu" style="display: none"><div><input type="checkbox" id="sdiff-HideUnch-cb" name="sdiff-HideUnch" value="true" onclick="SDiffUpdateHideUnch(&#39;sdiff-HideUnch-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideUnch(&#39;sdiff-HideUnch-cb&#39;)"> Hide unchanged portions (except top/bottom lines)</span></div><div><input type="checkbox" id="sdiff-HideNonMain-cb" name="sdiff-HideNonMain" value="true" onclick="SDiffUpdateHideNonMain(&#39;sdiff-HideNonMain-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideNonMain(&#39;sdiff-HideNonMain-cb&#39;)"> Hide non-essential portions (contact info, locations, etc.)</span></div><div style="display:none"><input type="checkbox" id="sdiff-HideKey-cb" name="sdiff-HideKey" value="true" onclick="SDiffUpdateHideKey(&#39;sdiff-HideKey-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideKey(&#39;sdiff-HideKey-cb&#39;)"> Hide key</span></div></div><h1>Changes to NCT00504075 on 2009_10_02</h1><div id="sdiff-key"><div id="sdiff-key-mb"><img id="sdiff-key-minmax" onclick="SDiffToggleHideKey(&#39;sdiff-HideKey-cb&#39;)" src="/archive/minmax.gif" alt="[+/-]" width="16" height="16" style="display:none" /><h2>Key</h2></div><img id="sdiff-key-img" src="/archive/sdiff-key.gif" alt="Key" /></div><div class="sdiff-changedesc"><em>Type of info changed: </em>Recruitment, Location/Contact, Misc.</div><div class="sdiff-view" id="sdiff-full" style="display: none"><table class="sdiff navLinks"><colgroup><col id="h-col" /><col id="a-col" /><col id="b-col" /></colgroup><tr><th class="sdiff-h" /><th class="sdiff-a"><div class="sdiff-prev"><a href="/archive/NCT00504075/2009_07_17/changes" title="Show changes from prior version to this one"><img src="/archive/prev.gif" alt="[Previous]" width="23" height="19" /></a></div><h2>Before</h2><h3><a href="/archive/NCT00504075/2009_07_17">(Updated 2009_07_17)</a></h3></th><th class="sdiff-b"><div class="sdiff-next"><a href="/archive/NCT00504075/2010_01_25/changes" title="Show changes from this version to next one"><img src="/archive/next.gif" alt="[Next]" width="23" height="19" /></a></div><h2>After</h2><h3><a href="/archive/NCT00504075/2009_10_02">(Updated 2009_10_02)</a></h3></th></tr>
<tr class="sdiff-unc" id="sdiff-chunk-f1"><td class="sdiff-h">1</td>
<td class="sdiff-a"><img id="sdiff-collapse-f0A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><img id="sdiff-collapse-f0A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-f0A-cdiv" class="sdiff-collapsed" title="The middle 69 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none"></div><div id="sdiff-collapse-f0A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  BioProducts</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  Bio Products Laboratory</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  GMX02</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT00504075</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;is_fda_regulated&gt;</div>
<div class="sdl2">  Yes</div>
<div class="sdl1 sdz">&lt;/is_fda_regulated&gt;</div>
<div class="sdl1 sds">&lt;is_section_801&gt;</div>
<div class="sdl2">  Yes</div>
<div class="sdl1 sdz">&lt;/is_section_801&gt;</div>
<div class="sdl1 sds">&lt;delayed_posting&gt;</div>
<div class="sdl2">  No</div>
<div class="sdl1 sdz">&lt;/delayed_posting&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  A Study to Find How Safe and Effective GAMMAPLEX&amp;#174; is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  A Phase III, Multicenter, Open-Label Study To Evaluate the Efficacy and Safety of GAMMAPLEX&amp;#174; in Chronic Idiopathic Thrombocytopenic Purpura</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Bio Products Laboratory</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;resp_party&gt;</div>
<div class="sdl2 sds">&lt;name_title&gt;</div>
<div class="sdl3">  James B Bussel, Principal Investigator</div>
<div class="sdl2 sdz">&lt;/name_title&gt;</div>
<div class="sdl2 sds">&lt;organization&gt;</div>
<div class="sdl3">  New York Presbyterian Hospital</div>
<div class="sdl2 sdz">&lt;/organization&gt;</div>
<div class="sdl1 sdz">&lt;/resp_party&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Food and Drug Administration</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl2 sds">&lt;has_dmc&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/has_dmc&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  The primary objective is to determine if BPL&amp;apos;s GAMMAPLEX raises the platelet count of subjects with chronic ITP to a threshold of 50 x 109/L, similar to that of a historical control.  The secondary objectives are:  1) to determine the safety of GAMMAPLEX at the dosage used in this study.  2) to determine if GAMMAPLEX maintains platelet counts of &amp;#179; 50 x 109/L in subjects with chronic ITP for a period of time similar to that of a historical control.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f0B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><img id="sdiff-collapse-f0B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-f0B-cdiv" class="sdiff-collapsed" title="The middle 69 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none"></div><div id="sdiff-collapse-f0B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  BioProducts</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  Bio Products Laboratory</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  GMX02</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT00504075</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;is_fda_regulated&gt;</div>
<div class="sdl2">  Yes</div>
<div class="sdl1 sdz">&lt;/is_fda_regulated&gt;</div>
<div class="sdl1 sds">&lt;is_section_801&gt;</div>
<div class="sdl2">  Yes</div>
<div class="sdl1 sdz">&lt;/is_section_801&gt;</div>
<div class="sdl1 sds">&lt;delayed_posting&gt;</div>
<div class="sdl2">  No</div>
<div class="sdl1 sdz">&lt;/delayed_posting&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  A Study to Find How Safe and Effective GAMMAPLEX&amp;#174; is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  A Phase III, Multicenter, Open-Label Study To Evaluate the Efficacy and Safety of GAMMAPLEX&amp;#174; in Chronic Idiopathic Thrombocytopenic Purpura</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Bio Products Laboratory</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;resp_party&gt;</div>
<div class="sdl2 sds">&lt;name_title&gt;</div>
<div class="sdl3">  James B Bussel, Principal Investigator</div>
<div class="sdl2 sdz">&lt;/name_title&gt;</div>
<div class="sdl2 sds">&lt;organization&gt;</div>
<div class="sdl3">  New York Presbyterian Hospital</div>
<div class="sdl2 sdz">&lt;/organization&gt;</div>
<div class="sdl1 sdz">&lt;/resp_party&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Food and Drug Administration</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl2 sds">&lt;has_dmc&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/has_dmc&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  The primary objective is to determine if BPL&amp;apos;s GAMMAPLEX raises the platelet count of subjects with chronic ITP to a threshold of 50 x 109/L, similar to that of a historical control.  The secondary objectives are:  1) to determine the safety of GAMMAPLEX at the dosage used in this study.  2) to determine if GAMMAPLEX maintains platelet counts of &amp;#179; 50 x 109/L in subjects with chronic ITP for a period of time similar to that of a historical control.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f2"><td class="sdiff-h">2</td>
<td class="sdiff-a"><div class="sdl3"><span class="sdwc">2009-07</span> </div>
</td>
<td class="sdiff-b"><div class="sdl3"><span class="sdwc">2009-10</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f3"><td class="sdiff-h">3</td>
<td class="sdiff-a"><img id="sdiff-collapse-f72A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f72&#39;)" style="display:none" /><img id="sdiff-collapse-f72A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f72&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-f72A-cdiv" class="sdiff-collapsed" title="The middle 237 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f72&#39;)" style="display:none"></div><div id="sdiff-collapse-f72A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2007-08</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sda">&lt;last_follow_up_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2010-05</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sda">&lt;primary_compl_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2010-05</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/primary_compl_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 3</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Non-Randomized</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Open Label</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Historical Control</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Single Group Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Safety/Efficacy Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;number_of_arms&gt;</div>
<div class="sdl2">  1</div>
<div class="sdl1 sdz">&lt;/number_of_arms&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  The primary objective is to determine if BPL&amp;apos;s GAMMAPLEX raises the platelet count of subjects with chronic ITP to a threshold of 50 x 109/L, similar to that of a historical control.</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  3 to 6  months</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  To determine the safety of GAMMAPLEX at the dosage used in this study and to determine if GAMMAPLEX maintains platelet counts of &amp;#179; 50 x 109/L in subjects with chronic ITP for a period of time similar to that of a historical control.</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  3 to 6 months</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sda">&lt;enrollment</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2">  31</div>
<div class="sdl1 sdz">&lt;/enrollment&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Chronic Idiopathic Thrombocytopenic Purpura</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Biological/Vaccine</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Gammaplex, intravenous immunoglobulin</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  The first course of GAMMAPLEX will be administered as an intravenous infusion of 1 g/kg on each of 2 consecutive days.  If required, a further 1 or 2 courses on the same dosage regimen may be administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Gammaplex</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Biological/Vaccine</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Gammaplex</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Gammaplex&amp;#174; contains 5 g/100 mL of human normal immunoglobulin         (i.e. 50 g/L, of which virtually 100% is IgG).  The first course of GAMMAPLEX will be administered as an intravenous infusion of 1 g/kg on each of 2 consecutive days.  If required, a further 1 or 2 courses on the same dosage regimen may be administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  N/app</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Biological/Vaccine</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Gammaplex</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Dosage form: Gammaplex&amp;#174; is a sterile liquid of 5 % w/v normal immunoglobulin.  Gammaplex&amp;#174; contains 5 g/100 mL of human normal immunoglobulin (i.e. 50 g/L, of which virtually 100% is IgG). The first course of GAMMAPLEX will be administered as an intravenous infusion of 1 g/kg on each of 2 consecutive days.  If required, a further 1 or 2 courses on the same dosage regimen may be administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Gammaplex</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria:</div>
<div class="sdl4">  1) Males and females aged between 6 and 70 years.  </div>
<div class="sdl4">  2) Confirmed diagnosis of chronic ITP of at least 6 months duration.</div>
<div class="sdl4">  3) Platelet count of less than or equal to 20 x 10 9/L at enrollment.  </div>
<div class="sdl4">  4) Absence of other conditions that, in the opinion of the investigator, could cause thrombocytopenia.  </div>
<div class="sdl4">  5) If subjects are currently being treated with corticosteroids the treatment regimen/dose must have been stable (for a minimum of 2 weeks before screening).  However, subjects must remain on a stable treatment regimen.  If there is any intent to alter the corticosteroid treatment regimen (e.g., tapering of corticosteroids) before Day 10, subjects may not be included in the study.  </div>
<div class="sdl4">  6) If subjects are currently being treated with cyclophosphamide, azathioprine or attenuated androgens, the treatment regimen and dose must have been stable for a minimum of 2 months before screening.  However, if there is any intent to alter the treatment regimen before Day 10, subjects may not be included in the study.  </div>
<div class="sdl4">  7) Splenectomized subjects and both Rh(D)+ and Rh(D)- subjects may be included.  </div>
<div class="sdl4">  8) The subject has signed an informed consent form (if at least 18 years old) or the subject&amp;apos;s parent or legal guardian has signed the informed consent form.  If appropriate, the subject has signed a child assent form.  </div>
<div class="sdl4">  9) If a subject is a female of child-bearing potential, she must have a negative result on a urine-based HCG pregnancy test.  </div>
<div class="sdl4">  10) If a subject is a female who is or becomes sexually active, she must practice contraception by using a method of proven reliability for the duration of the study. </div>
<div class="sdl4">  </div>
<div class="sdl4">  Exclusion Criteria:</div>
<div class="sdl4">  1) The subject has a history of any severe or anaphylactic reaction to blood or any blood-derived product, or any severe reaction to IGIV or any other IgG preparation.  </div>
<div class="sdl4">  2) The subject is known to be intolerant to any component of the investigational product.  </div>
<div class="sdl4">  3) The subject has received any live virus vaccine within the last 3 months.  </div>
<div class="sdl4">  4) The subject has received an IGIV preparation within 1 month prior to screening.  </div>
<div class="sdl4">  5) The subject is currently receiving, or has received, any investigational agent within the 1 month prior to screening.    </div>
<div class="sdl4">  6) The subject has received any blood, blood product, or blood derivative within the 1 month prior to screening.  </div>
<div class="sdl4">  7) The subject has received Rituximab within the 3 months before screening</div>
<div class="sdl4">  8) The subject is pregnant or is nursing.  </div>
<div class="sdl4">  9) The subject is positive for any of the following at screening: HBsAg, NAT for HCV, NAT for HIV, Antibodies to HCV or HIV 1 or 2. </div>
<div class="sdl4">  10) The subject, at screening, has levels greater than 2.5 times the upper limit of normal, as defined by the central laboratory, of alanine aminotransferase or aspartate aminotransferase.  </div>
<div class="sdl4">  11) The subject has a severe renal impairment (defined as serum creatinine greater than 2 times the upper limit of normal or BUN greater than 2.5 times the upper limit of normal for the range of the laboratory doing the analysis); the subject is on dialysis; the subject has a history of acute renal failure.</div>
<div class="sdl4">  12) The subject is known to have abused alcohol, opiates, psychotropic agents, or other chemicals or drugs within the past 12 months.  </div>
<div class="sdl4">  13) The subject has a history of deep vein thrombosis (DVT) or thrombotic complications of IGIV therapy.  </div>
<div class="sdl4">  14) The subject has any history or sign of hyperviscosity, transient ischemic attack (TIA), stroke, other thromboembolic event, or unstable angina.  </div>
<div class="sdl4">  15) The subject suffers from any acute or chronic medical conditions (e.g., renal disease or predisposing conditions for renal disease, coronary artery disease, or protein losing enteropathy) that, in the opinion of the investigator, may interfere with the conduct of the study.  </div>
<div class="sdl4">  16) The subject has an acquired medical condition, such as chronic lymphocytic leukemia, lymphoma, multiple myeloma, chronic or recurrent neutropenia (defined as an absolute neutrophil count (ANC) &amp;lt; 1 x 109/L).  </div>
<div class="sdl4">  17) The subject has non-controlled arterial hypertension (systolic blood pressure &amp;gt;160 mmHg and/or diastolic blood pressure &amp;gt;90 mmHg).  </div>
<div class="sdl4">  18) The subject is anemic (hemoglobin &amp;lt;10 g/dL) at screening.  </div>
<div class="sdl4">  19) The subject is unlikely to adhere to the protocol requirements of the study or is likely to be uncooperative..</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  6 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl3">  70 Years</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Principal Investigator</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  James B Bussel, MD</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  New York Presbyterian Hospital</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;location&gt;</div>
<div class="sdl2 sds">&lt;facility&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Mid Florida Hematology &amp;amp; Oncology</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;address&gt;</div>
<div class="sdl4 sds">&lt;city&gt;</div>
<div class="sdl5">  Orange City</div>
<div class="sdl4 sdz">&lt;/city&gt;</div>
<div class="sdl4 sds">&lt;state&gt;</div>
<div class="sdl5">  Florida</div>
<div class="sdl4 sdz">&lt;/state&gt;</div>
<div class="sdl4 sds">&lt;zip&gt;</div>
<div class="sdl5">  32763</div>
<div class="sdl4 sdz">&lt;/zip&gt;</div>
<div class="sdl4 sds">&lt;country&gt;</div>
<div class="sdl5">  United States</div>
<div class="sdl4 sdz">&lt;/country&gt;</div>
<div class="sdl3 sdz">&lt;/address&gt;</div>
<div class="sdl2 sdz">&lt;/facility&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Sandy Davis</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;phone&gt;</div>
<div class="sdl4">  386-566-3303</div>
<div class="sdl3 sdz">&lt;/phone&gt;</div>
<div class="sdl3 sds">&lt;phone_ext&gt;</div>
<div class="sdl3 sdz">&lt;/phone_ext&gt;</div>
<div class="sdl3 sds">&lt;email&gt;</div>
<div class="sdl4">  swarrington@auafl.com</div>
<div class="sdl3 sdz">&lt;/email&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Principal Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Gregory Ortega, MD</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sdz">&lt;/location&gt;</div>
<div class="sdl1 sds">&lt;location&gt;</div>
<div class="sdl2 sds">&lt;facility&gt;</div>
</div><div class="sdl3 sds">&lt;name&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f72B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f72&#39;)" style="display:none" /><img id="sdiff-collapse-f72B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f72&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-f72B-cdiv" class="sdiff-collapsed" title="The middle 237 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f72&#39;)" style="display:none"></div><div id="sdiff-collapse-f72B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2007-08</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sda">&lt;last_follow_up_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2010-05</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sda">&lt;primary_compl_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2010-05</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/primary_compl_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 3</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Non-Randomized</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Open Label</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Historical Control</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Single Group Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Safety/Efficacy Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;number_of_arms&gt;</div>
<div class="sdl2">  1</div>
<div class="sdl1 sdz">&lt;/number_of_arms&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  The primary objective is to determine if BPL&amp;apos;s GAMMAPLEX raises the platelet count of subjects with chronic ITP to a threshold of 50 x 109/L, similar to that of a historical control.</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  3 to 6  months</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  To determine the safety of GAMMAPLEX at the dosage used in this study and to determine if GAMMAPLEX maintains platelet counts of &amp;#179; 50 x 109/L in subjects with chronic ITP for a period of time similar to that of a historical control.</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  3 to 6 months</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sda">&lt;enrollment</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2">  31</div>
<div class="sdl1 sdz">&lt;/enrollment&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Chronic Idiopathic Thrombocytopenic Purpura</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Biological/Vaccine</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Gammaplex, intravenous immunoglobulin</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  The first course of GAMMAPLEX will be administered as an intravenous infusion of 1 g/kg on each of 2 consecutive days.  If required, a further 1 or 2 courses on the same dosage regimen may be administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Gammaplex</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Biological/Vaccine</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Gammaplex</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Gammaplex&amp;#174; contains 5 g/100 mL of human normal immunoglobulin         (i.e. 50 g/L, of which virtually 100% is IgG).  The first course of GAMMAPLEX will be administered as an intravenous infusion of 1 g/kg on each of 2 consecutive days.  If required, a further 1 or 2 courses on the same dosage regimen may be administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  N/app</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Biological/Vaccine</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Gammaplex</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Dosage form: Gammaplex&amp;#174; is a sterile liquid of 5 % w/v normal immunoglobulin.  Gammaplex&amp;#174; contains 5 g/100 mL of human normal immunoglobulin (i.e. 50 g/L, of which virtually 100% is IgG). The first course of GAMMAPLEX will be administered as an intravenous infusion of 1 g/kg on each of 2 consecutive days.  If required, a further 1 or 2 courses on the same dosage regimen may be administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Gammaplex</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria:</div>
<div class="sdl4">  1) Males and females aged between 6 and 70 years.  </div>
<div class="sdl4">  2) Confirmed diagnosis of chronic ITP of at least 6 months duration.</div>
<div class="sdl4">  3) Platelet count of less than or equal to 20 x 10 9/L at enrollment.  </div>
<div class="sdl4">  4) Absence of other conditions that, in the opinion of the investigator, could cause thrombocytopenia.  </div>
<div class="sdl4">  5) If subjects are currently being treated with corticosteroids the treatment regimen/dose must have been stable (for a minimum of 2 weeks before screening).  However, subjects must remain on a stable treatment regimen.  If there is any intent to alter the corticosteroid treatment regimen (e.g., tapering of corticosteroids) before Day 10, subjects may not be included in the study.  </div>
<div class="sdl4">  6) If subjects are currently being treated with cyclophosphamide, azathioprine or attenuated androgens, the treatment regimen and dose must have been stable for a minimum of 2 months before screening.  However, if there is any intent to alter the treatment regimen before Day 10, subjects may not be included in the study.  </div>
<div class="sdl4">  7) Splenectomized subjects and both Rh(D)+ and Rh(D)- subjects may be included.  </div>
<div class="sdl4">  8) The subject has signed an informed consent form (if at least 18 years old) or the subject&amp;apos;s parent or legal guardian has signed the informed consent form.  If appropriate, the subject has signed a child assent form.  </div>
<div class="sdl4">  9) If a subject is a female of child-bearing potential, she must have a negative result on a urine-based HCG pregnancy test.  </div>
<div class="sdl4">  10) If a subject is a female who is or becomes sexually active, she must practice contraception by using a method of proven reliability for the duration of the study. </div>
<div class="sdl4">  </div>
<div class="sdl4">  Exclusion Criteria:</div>
<div class="sdl4">  1) The subject has a history of any severe or anaphylactic reaction to blood or any blood-derived product, or any severe reaction to IGIV or any other IgG preparation.  </div>
<div class="sdl4">  2) The subject is known to be intolerant to any component of the investigational product.  </div>
<div class="sdl4">  3) The subject has received any live virus vaccine within the last 3 months.  </div>
<div class="sdl4">  4) The subject has received an IGIV preparation within 1 month prior to screening.  </div>
<div class="sdl4">  5) The subject is currently receiving, or has received, any investigational agent within the 1 month prior to screening.    </div>
<div class="sdl4">  6) The subject has received any blood, blood product, or blood derivative within the 1 month prior to screening.  </div>
<div class="sdl4">  7) The subject has received Rituximab within the 3 months before screening</div>
<div class="sdl4">  8) The subject is pregnant or is nursing.  </div>
<div class="sdl4">  9) The subject is positive for any of the following at screening: HBsAg, NAT for HCV, NAT for HIV, Antibodies to HCV or HIV 1 or 2. </div>
<div class="sdl4">  10) The subject, at screening, has levels greater than 2.5 times the upper limit of normal, as defined by the central laboratory, of alanine aminotransferase or aspartate aminotransferase.  </div>
<div class="sdl4">  11) The subject has a severe renal impairment (defined as serum creatinine greater than 2 times the upper limit of normal or BUN greater than 2.5 times the upper limit of normal for the range of the laboratory doing the analysis); the subject is on dialysis; the subject has a history of acute renal failure.</div>
<div class="sdl4">  12) The subject is known to have abused alcohol, opiates, psychotropic agents, or other chemicals or drugs within the past 12 months.  </div>
<div class="sdl4">  13) The subject has a history of deep vein thrombosis (DVT) or thrombotic complications of IGIV therapy.  </div>
<div class="sdl4">  14) The subject has any history or sign of hyperviscosity, transient ischemic attack (TIA), stroke, other thromboembolic event, or unstable angina.  </div>
<div class="sdl4">  15) The subject suffers from any acute or chronic medical conditions (e.g., renal disease or predisposing conditions for renal disease, coronary artery disease, or protein losing enteropathy) that, in the opinion of the investigator, may interfere with the conduct of the study.  </div>
<div class="sdl4">  16) The subject has an acquired medical condition, such as chronic lymphocytic leukemia, lymphoma, multiple myeloma, chronic or recurrent neutropenia (defined as an absolute neutrophil count (ANC) &amp;lt; 1 x 109/L).  </div>
<div class="sdl4">  17) The subject has non-controlled arterial hypertension (systolic blood pressure &amp;gt;160 mmHg and/or diastolic blood pressure &amp;gt;90 mmHg).  </div>
<div class="sdl4">  18) The subject is anemic (hemoglobin &amp;lt;10 g/dL) at screening.  </div>
<div class="sdl4">  19) The subject is unlikely to adhere to the protocol requirements of the study or is likely to be uncooperative..</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  6 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl3">  70 Years</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Principal Investigator</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  James B Bussel, MD</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  New York Presbyterian Hospital</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;location&gt;</div>
<div class="sdl2 sds">&lt;facility&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Mid Florida Hematology &amp;amp; Oncology</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;address&gt;</div>
<div class="sdl4 sds">&lt;city&gt;</div>
<div class="sdl5">  Orange City</div>
<div class="sdl4 sdz">&lt;/city&gt;</div>
<div class="sdl4 sds">&lt;state&gt;</div>
<div class="sdl5">  Florida</div>
<div class="sdl4 sdz">&lt;/state&gt;</div>
<div class="sdl4 sds">&lt;zip&gt;</div>
<div class="sdl5">  32763</div>
<div class="sdl4 sdz">&lt;/zip&gt;</div>
<div class="sdl4 sds">&lt;country&gt;</div>
<div class="sdl5">  United States</div>
<div class="sdl4 sdz">&lt;/country&gt;</div>
<div class="sdl3 sdz">&lt;/address&gt;</div>
<div class="sdl2 sdz">&lt;/facility&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Sandy Davis</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;phone&gt;</div>
<div class="sdl4">  386-566-3303</div>
<div class="sdl3 sdz">&lt;/phone&gt;</div>
<div class="sdl3 sds">&lt;phone_ext&gt;</div>
<div class="sdl3 sdz">&lt;/phone_ext&gt;</div>
<div class="sdl3 sds">&lt;email&gt;</div>
<div class="sdl4">  swarrington@auafl.com</div>
<div class="sdl3 sdz">&lt;/email&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Principal Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Gregory Ortega, MD</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sdz">&lt;/location&gt;</div>
<div class="sdl1 sds">&lt;location&gt;</div>
<div class="sdl2 sds">&lt;facility&gt;</div>
</div><div class="sdl3 sds">&lt;name&gt;</div>
</td>
</tr>
<tr class="sdiff-add" id="sdiff-chunk-f4"><td class="sdiff-h">4</td>
<td class="sdiff-a"><div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
<div class="sdl4"></div>
</td>
<td class="sdiff-b"><div class="sdl4">  Rush University Medical Center</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;address&gt;</div>
<div class="sdl4 sds">&lt;city&gt;</div>
<div class="sdl5">  Chicago</div>
<div class="sdl4 sdz">&lt;/city&gt;</div>
<div class="sdl4 sds">&lt;state&gt;</div>
<div class="sdl5">  Illinois</div>
<div class="sdl4 sdz">&lt;/state&gt;</div>
<div class="sdl4 sds">&lt;zip&gt;</div>
<div class="sdl5">  60612</div>
<div class="sdl4 sdz">&lt;/zip&gt;</div>
<div class="sdl4 sds">&lt;country&gt;</div>
<div class="sdl5">  United States</div>
<div class="sdl4 sdz">&lt;/country&gt;</div>
<div class="sdl3 sdz">&lt;/address&gt;</div>
<div class="sdl2 sdz">&lt;/facility&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Not yet recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Lisa N. Boggio, MD</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;phone&gt;</div>
<div class="sdl4">  312-942-5157</div>
<div class="sdl3 sdz">&lt;/phone&gt;</div>
<div class="sdl3 sds">&lt;phone_ext&gt;</div>
<div class="sdl3 sdz">&lt;/phone_ext&gt;</div>
<div class="sdl3 sds">&lt;email&gt;</div>
<div class="sdl4">  Lisa_Boggio@rush.edu</div>
<div class="sdl3 sdz">&lt;/email&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Principal Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Lisa N. Boggio, MD</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sdz">&lt;/location&gt;</div>
<div class="sdl1 sds">&lt;location&gt;</div>
<div class="sdl2 sds">&lt;facility&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f5"><td class="sdiff-h">5</td>
<td class="sdiff-a"><img id="sdiff-collapse-f356A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f356&#39;)" style="display:none" /><img id="sdiff-collapse-f356A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f356&#39;)" style="display:none" /><div class="sdl4">  Center for Cancer &amp;amp; Blood Disorders</div>
<div id="sdiff-collapse-f356A-cdiv" class="sdiff-collapsed" title="The middle 16 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f356&#39;)" style="display:none"></div><div id="sdiff-collapse-f356A-ediv" class="sdiff-expanded"><div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;address&gt;</div>
<div class="sdl4 sds">&lt;city&gt;</div>
<div class="sdl5">  Bethesda</div>
<div class="sdl4 sdz">&lt;/city&gt;</div>
<div class="sdl4 sds">&lt;state&gt;</div>
<div class="sdl5">  Maryland</div>
<div class="sdl4 sdz">&lt;/state&gt;</div>
<div class="sdl4 sds">&lt;zip&gt;</div>
<div class="sdl5">  20817</div>
<div class="sdl4 sdz">&lt;/zip&gt;</div>
<div class="sdl4 sds">&lt;country&gt;</div>
<div class="sdl5">  United States</div>
<div class="sdl4 sdz">&lt;/country&gt;</div>
<div class="sdl3 sdz">&lt;/address&gt;</div>
<div class="sdl2 sdz">&lt;/facility&gt;</div>
</div><div class="sdl2 sds">&lt;status&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f356B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f356&#39;)" style="display:none" /><img id="sdiff-collapse-f356B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f356&#39;)" style="display:none" /><div class="sdl4">  Center for Cancer &amp;amp; Blood Disorders</div>
<div id="sdiff-collapse-f356B-cdiv" class="sdiff-collapsed" title="The middle 16 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f356&#39;)" style="display:none"></div><div id="sdiff-collapse-f356B-ediv" class="sdiff-expanded"><div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;address&gt;</div>
<div class="sdl4 sds">&lt;city&gt;</div>
<div class="sdl5">  Bethesda</div>
<div class="sdl4 sdz">&lt;/city&gt;</div>
<div class="sdl4 sds">&lt;state&gt;</div>
<div class="sdl5">  Maryland</div>
<div class="sdl4 sdz">&lt;/state&gt;</div>
<div class="sdl4 sds">&lt;zip&gt;</div>
<div class="sdl5">  20817</div>
<div class="sdl4 sdz">&lt;/zip&gt;</div>
<div class="sdl4 sds">&lt;country&gt;</div>
<div class="sdl5">  United States</div>
<div class="sdl4 sdz">&lt;/country&gt;</div>
<div class="sdl3 sdz">&lt;/address&gt;</div>
<div class="sdl2 sdz">&lt;/facility&gt;</div>
</div><div class="sdl2 sds">&lt;status&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f6"><td class="sdiff-h">6</td>
<td class="sdiff-a"><div class="sdl3"><span class="sdwd">Active,</span> <span class="sdwd">not</span> <span class="sdwd">recruiting</span>  </div>
</td>
<td class="sdiff-b"><div class="sdl3">   <span class="sdwa">Terminated</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f7"><td class="sdiff-h">7</td>
<td class="sdiff-a"><img id="sdiff-collapse-f375A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f375&#39;)" style="display:none" /><img id="sdiff-collapse-f375A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f375&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/status&gt;</div>
<div id="sdiff-collapse-f375A-cdiv" class="sdiff-collapsed" title="The middle 87 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f375&#39;)" style="display:none"></div><div id="sdiff-collapse-f375A-ediv" class="sdiff-expanded"><div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Natalie Bongiorno, RN, MSHS</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;phone&gt;</div>
<div class="sdl4">  301-571-2016</div>
<div class="sdl3 sdz">&lt;/phone&gt;</div>
<div class="sdl3 sds">&lt;phone_ext&gt;</div>
<div class="sdl3 sdz">&lt;/phone_ext&gt;</div>
<div class="sdl3 sds">&lt;email&gt;</div>
<div class="sdl4">  nbongiorno@ccbdmd.com</div>
<div class="sdl3 sdz">&lt;/email&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Principal Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Victor Priego, MD</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sdz">&lt;/location&gt;</div>
<div class="sdl1 sds">&lt;location&gt;</div>
<div class="sdl2 sds">&lt;facility&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  New York Hospital / Cornell University, Division of Pediatrics</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;address&gt;</div>
<div class="sdl4 sds">&lt;city&gt;</div>
<div class="sdl5">  New York</div>
<div class="sdl4 sdz">&lt;/city&gt;</div>
<div class="sdl4 sds">&lt;state&gt;</div>
<div class="sdl5">  New York</div>
<div class="sdl4 sdz">&lt;/state&gt;</div>
<div class="sdl4 sds">&lt;zip&gt;</div>
<div class="sdl5">  10021</div>
<div class="sdl4 sdz">&lt;/zip&gt;</div>
<div class="sdl4 sds">&lt;country&gt;</div>
<div class="sdl5">  United States</div>
<div class="sdl4 sdz">&lt;/country&gt;</div>
<div class="sdl3 sdz">&lt;/address&gt;</div>
<div class="sdl2 sdz">&lt;/facility&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Jared Levan</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;phone&gt;</div>
<div class="sdl4">  212-746-3423</div>
<div class="sdl3 sdz">&lt;/phone&gt;</div>
<div class="sdl3 sds">&lt;phone_ext&gt;</div>
<div class="sdl3 sdz">&lt;/phone_ext&gt;</div>
<div class="sdl3 sds">&lt;email&gt;</div>
<div class="sdl4">  jal2029@med.cornell.edu</div>
<div class="sdl3 sdz">&lt;/email&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Principal Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  James B Bussel, MD</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sdz">&lt;/location&gt;</div>
<div class="sdl1 sds">&lt;location&gt;</div>
<div class="sdl2 sds">&lt;facility&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Department of Pediatrics, SUNY at Stony Brook</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;address&gt;</div>
<div class="sdl4 sds">&lt;city&gt;</div>
<div class="sdl5">  Stony Brook</div>
<div class="sdl4 sdz">&lt;/city&gt;</div>
<div class="sdl4 sds">&lt;state&gt;</div>
<div class="sdl5">  New York</div>
<div class="sdl4 sdz">&lt;/state&gt;</div>
<div class="sdl4 sds">&lt;zip&gt;</div>
<div class="sdl5">  11794-8111</div>
<div class="sdl4 sdz">&lt;/zip&gt;</div>
<div class="sdl4 sds">&lt;country&gt;</div>
<div class="sdl5">  United States</div>
<div class="sdl4 sdz">&lt;/country&gt;</div>
<div class="sdl3 sdz">&lt;/address&gt;</div>
<div class="sdl2 sdz">&lt;/facility&gt;</div>
</div><div class="sdl2 sds">&lt;status&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f375B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f375&#39;)" style="display:none" /><img id="sdiff-collapse-f375B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f375&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/status&gt;</div>
<div id="sdiff-collapse-f375B-cdiv" class="sdiff-collapsed" title="The middle 87 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f375&#39;)" style="display:none"></div><div id="sdiff-collapse-f375B-ediv" class="sdiff-expanded"><div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Natalie Bongiorno, RN, MSHS</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;phone&gt;</div>
<div class="sdl4">  301-571-2016</div>
<div class="sdl3 sdz">&lt;/phone&gt;</div>
<div class="sdl3 sds">&lt;phone_ext&gt;</div>
<div class="sdl3 sdz">&lt;/phone_ext&gt;</div>
<div class="sdl3 sds">&lt;email&gt;</div>
<div class="sdl4">  nbongiorno@ccbdmd.com</div>
<div class="sdl3 sdz">&lt;/email&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Principal Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Victor Priego, MD</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sdz">&lt;/location&gt;</div>
<div class="sdl1 sds">&lt;location&gt;</div>
<div class="sdl2 sds">&lt;facility&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  New York Hospital / Cornell University, Division of Pediatrics</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;address&gt;</div>
<div class="sdl4 sds">&lt;city&gt;</div>
<div class="sdl5">  New York</div>
<div class="sdl4 sdz">&lt;/city&gt;</div>
<div class="sdl4 sds">&lt;state&gt;</div>
<div class="sdl5">  New York</div>
<div class="sdl4 sdz">&lt;/state&gt;</div>
<div class="sdl4 sds">&lt;zip&gt;</div>
<div class="sdl5">  10021</div>
<div class="sdl4 sdz">&lt;/zip&gt;</div>
<div class="sdl4 sds">&lt;country&gt;</div>
<div class="sdl5">  United States</div>
<div class="sdl4 sdz">&lt;/country&gt;</div>
<div class="sdl3 sdz">&lt;/address&gt;</div>
<div class="sdl2 sdz">&lt;/facility&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Jared Levan</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;phone&gt;</div>
<div class="sdl4">  212-746-3423</div>
<div class="sdl3 sdz">&lt;/phone&gt;</div>
<div class="sdl3 sds">&lt;phone_ext&gt;</div>
<div class="sdl3 sdz">&lt;/phone_ext&gt;</div>
<div class="sdl3 sds">&lt;email&gt;</div>
<div class="sdl4">  jal2029@med.cornell.edu</div>
<div class="sdl3 sdz">&lt;/email&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Principal Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  James B Bussel, MD</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sdz">&lt;/location&gt;</div>
<div class="sdl1 sds">&lt;location&gt;</div>
<div class="sdl2 sds">&lt;facility&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Department of Pediatrics, SUNY at Stony Brook</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;address&gt;</div>
<div class="sdl4 sds">&lt;city&gt;</div>
<div class="sdl5">  Stony Brook</div>
<div class="sdl4 sdz">&lt;/city&gt;</div>
<div class="sdl4 sds">&lt;state&gt;</div>
<div class="sdl5">  New York</div>
<div class="sdl4 sdz">&lt;/state&gt;</div>
<div class="sdl4 sds">&lt;zip&gt;</div>
<div class="sdl5">  11794-8111</div>
<div class="sdl4 sdz">&lt;/zip&gt;</div>
<div class="sdl4 sds">&lt;country&gt;</div>
<div class="sdl5">  United States</div>
<div class="sdl4 sdz">&lt;/country&gt;</div>
<div class="sdl3 sdz">&lt;/address&gt;</div>
<div class="sdl2 sdz">&lt;/facility&gt;</div>
</div><div class="sdl2 sds">&lt;status&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f8"><td class="sdiff-h">8</td>
<td class="sdiff-a"><div class="sdl3"><span class="sdwd">Active,</span> <span class="sdwd">not</span> <span class="sdwd">recruiting</span>  </div>
</td>
<td class="sdiff-b"><div class="sdl3">   <span class="sdwa">Terminated</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f9"><td class="sdiff-h">9</td>
<td class="sdiff-a"><img id="sdiff-collapse-f465A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f465&#39;)" style="display:none" /><img id="sdiff-collapse-f465A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f465&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/status&gt;</div>
<div id="sdiff-collapse-f465A-cdiv" class="sdiff-collapsed" title="The middle 66 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f465&#39;)" style="display:none"></div><div id="sdiff-collapse-f465A-ediv" class="sdiff-expanded"><div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Carol Martin</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;phone&gt;</div>
<div class="sdl4">  631-638-0838</div>
<div class="sdl3 sdz">&lt;/phone&gt;</div>
<div class="sdl3 sds">&lt;phone_ext&gt;</div>
<div class="sdl3 sdz">&lt;/phone_ext&gt;</div>
<div class="sdl3 sds">&lt;email&gt;</div>
<div class="sdl4">  caamartin@notes.cc.sunysb.edu</div>
<div class="sdl3 sdz">&lt;/email&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Principal Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Robert Parker, MD</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sdz">&lt;/location&gt;</div>
<div class="sdl1 sds">&lt;location&gt;</div>
<div class="sdl2 sds">&lt;facility&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Oregon Health &amp;amp; Science University</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;address&gt;</div>
<div class="sdl4 sds">&lt;city&gt;</div>
<div class="sdl5">  Portland</div>
<div class="sdl4 sdz">&lt;/city&gt;</div>
<div class="sdl4 sds">&lt;state&gt;</div>
<div class="sdl5">  Oregon</div>
<div class="sdl4 sdz">&lt;/state&gt;</div>
<div class="sdl4 sds">&lt;zip&gt;</div>
<div class="sdl5">  97239</div>
<div class="sdl4 sdz">&lt;/zip&gt;</div>
<div class="sdl4 sds">&lt;country&gt;</div>
<div class="sdl5">  United States</div>
<div class="sdl4 sdz">&lt;/country&gt;</div>
<div class="sdl3 sdz">&lt;/address&gt;</div>
<div class="sdl2 sdz">&lt;/facility&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Jenifer Borruel Rector, RN BSN CCRC</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;phone&gt;</div>
<div class="sdl4">  503-494-7187</div>
<div class="sdl3 sdz">&lt;/phone&gt;</div>
<div class="sdl3 sds">&lt;phone_ext&gt;</div>
<div class="sdl3 sdz">&lt;/phone_ext&gt;</div>
<div class="sdl3 sds">&lt;email&gt;</div>
<div class="sdl4">  borruelr@ohsu.edu</div>
<div class="sdl3 sdz">&lt;/email&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Principal Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Lynn Boshkov, MD</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
</div><div class="sdl1 sdz">&lt;/location&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f465B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f465&#39;)" style="display:none" /><img id="sdiff-collapse-f465B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f465&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/status&gt;</div>
<div id="sdiff-collapse-f465B-cdiv" class="sdiff-collapsed" title="The middle 66 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f465&#39;)" style="display:none"></div><div id="sdiff-collapse-f465B-ediv" class="sdiff-expanded"><div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Carol Martin</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;phone&gt;</div>
<div class="sdl4">  631-638-0838</div>
<div class="sdl3 sdz">&lt;/phone&gt;</div>
<div class="sdl3 sds">&lt;phone_ext&gt;</div>
<div class="sdl3 sdz">&lt;/phone_ext&gt;</div>
<div class="sdl3 sds">&lt;email&gt;</div>
<div class="sdl4">  caamartin@notes.cc.sunysb.edu</div>
<div class="sdl3 sdz">&lt;/email&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Principal Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Robert Parker, MD</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sdz">&lt;/location&gt;</div>
<div class="sdl1 sds">&lt;location&gt;</div>
<div class="sdl2 sds">&lt;facility&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Oregon Health &amp;amp; Science University</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;address&gt;</div>
<div class="sdl4 sds">&lt;city&gt;</div>
<div class="sdl5">  Portland</div>
<div class="sdl4 sdz">&lt;/city&gt;</div>
<div class="sdl4 sds">&lt;state&gt;</div>
<div class="sdl5">  Oregon</div>
<div class="sdl4 sdz">&lt;/state&gt;</div>
<div class="sdl4 sds">&lt;zip&gt;</div>
<div class="sdl5">  97239</div>
<div class="sdl4 sdz">&lt;/zip&gt;</div>
<div class="sdl4 sds">&lt;country&gt;</div>
<div class="sdl5">  United States</div>
<div class="sdl4 sdz">&lt;/country&gt;</div>
<div class="sdl3 sdz">&lt;/address&gt;</div>
<div class="sdl2 sdz">&lt;/facility&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Jenifer Borruel Rector, RN BSN CCRC</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;phone&gt;</div>
<div class="sdl4">  503-494-7187</div>
<div class="sdl3 sdz">&lt;/phone&gt;</div>
<div class="sdl3 sds">&lt;phone_ext&gt;</div>
<div class="sdl3 sdz">&lt;/phone_ext&gt;</div>
<div class="sdl3 sds">&lt;email&gt;</div>
<div class="sdl4">  borruelr@ohsu.edu</div>
<div class="sdl3 sdz">&lt;/email&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Principal Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Lynn Boshkov, MD</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
</div><div class="sdl1 sdz">&lt;/location&gt;</div>
</td>
</tr>
<tr class="sdiff-add" id="sdiff-chunk-f10"><td class="sdiff-h">10</td>
<td class="sdiff-a"><div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
<div class="sdl1"></div>
</td>
<td class="sdiff-b"><div class="sdl1 sds">&lt;location&gt;</div>
<div class="sdl2 sds">&lt;facility&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Cancer Care Centers of South Texas</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;address&gt;</div>
<div class="sdl4 sds">&lt;city&gt;</div>
<div class="sdl5">  San Antonio</div>
<div class="sdl4 sdz">&lt;/city&gt;</div>
<div class="sdl4 sds">&lt;state&gt;</div>
<div class="sdl5">  Texas</div>
<div class="sdl4 sdz">&lt;/state&gt;</div>
<div class="sdl4 sds">&lt;zip&gt;</div>
<div class="sdl5">  78229</div>
<div class="sdl4 sdz">&lt;/zip&gt;</div>
<div class="sdl4 sds">&lt;country&gt;</div>
<div class="sdl5">  United States</div>
<div class="sdl4 sdz">&lt;/country&gt;</div>
<div class="sdl3 sdz">&lt;/address&gt;</div>
<div class="sdl2 sdz">&lt;/facility&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Terminated</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Joanne Hardy, RN</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;phone&gt;</div>
<div class="sdl4">  210-595-5683</div>
<div class="sdl3 sdz">&lt;/phone&gt;</div>
<div class="sdl3 sds">&lt;phone_ext&gt;</div>
<div class="sdl3 sdz">&lt;/phone_ext&gt;</div>
<div class="sdl3 sds">&lt;email&gt;</div>
<div class="sdl4">  joanne.hardy@usoncology.com</div>
<div class="sdl3 sdz">&lt;/email&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Principal Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Roger M Lyons, MD</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sdz">&lt;/location&gt;</div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f11"><td class="sdiff-h">11</td>
<td class="sdiff-a"><img id="sdiff-collapse-f578A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f578&#39;)" style="display:none" /><img id="sdiff-collapse-f578A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f578&#39;)" style="display:none" /><div class="sdl1 sds">&lt;see_also&gt;</div>
<div id="sdiff-collapse-f578A-cdiv" class="sdiff-collapsed" title="The middle 21 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f578&#39;)" style="display:none"></div><div id="sdiff-collapse-f578A-ediv" class="sdiff-expanded"><div class="sdl2 sds">&lt;annotation&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Sponsor website</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/annotation&gt;</div>
<div class="sdl2 sds">&lt;url&gt;</div>
<div class="sdl3">  http://www.bpl.co.uk</div>
<div class="sdl2 sdz">&lt;/url&gt;</div>
<div class="sdl1 sdz">&lt;/see_also&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Idiopathic Thrombocytopenic Purpura</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Bleeding disorders</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Immune System and Disorders</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2007-07-18</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
</div><div class="sdl1 sds">&lt;last_release_date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f578B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f578&#39;)" style="display:none" /><img id="sdiff-collapse-f578B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f578&#39;)" style="display:none" /><div class="sdl1 sds">&lt;see_also&gt;</div>
<div id="sdiff-collapse-f578B-cdiv" class="sdiff-collapsed" title="The middle 21 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f578&#39;)" style="display:none"></div><div id="sdiff-collapse-f578B-ediv" class="sdiff-expanded"><div class="sdl2 sds">&lt;annotation&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Sponsor website</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/annotation&gt;</div>
<div class="sdl2 sds">&lt;url&gt;</div>
<div class="sdl3">  http://www.bpl.co.uk</div>
<div class="sdl2 sdz">&lt;/url&gt;</div>
<div class="sdl1 sdz">&lt;/see_also&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Idiopathic Thrombocytopenic Purpura</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Bleeding disorders</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Immune System and Disorders</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2007-07-18</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
</div><div class="sdl1 sds">&lt;last_release_date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f12"><td class="sdiff-h">12</td>
<td class="sdiff-a"><div class="sdl2"><span class="sdwc">2009-07-17</span> </div>
</td>
<td class="sdiff-b"><div class="sdl2"><span class="sdwc">2009-10-02</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f13"><td class="sdiff-h">13</td>
<td class="sdiff-a"><img id="sdiff-collapse-f602A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f602&#39;)" style="display:none" /><img id="sdiff-collapse-f602A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f602&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
<div id="sdiff-collapse-f602A-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f602&#39;)" style="display:none"></div><div id="sdiff-collapse-f602A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;init_disposition_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_disposition_release_date&gt;</div>
<div class="sdl1 sds">&lt;init_results_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_results_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f602B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f602&#39;)" style="display:none" /><img id="sdiff-collapse-f602B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f602&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
<div id="sdiff-collapse-f602B-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f602&#39;)" style="display:none"></div><div id="sdiff-collapse-f602B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;init_disposition_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_disposition_release_date&gt;</div>
<div class="sdl1 sds">&lt;init_results_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_results_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
</tr>

</table></div><div class="sdiff-view" id="sdiff-main" style="display: block"><table class="sdiff navLinks"><colgroup><col id="h-col" /><col id="a-col" /><col id="b-col" /></colgroup><tr><th class="sdiff-h" /><th class="sdiff-a"><div class="sdiff-prev"><a href="/archive/NCT00504075/2009_07_17/changes" title="Show changes from prior version to this one"><img src="/archive/prev.gif" alt="[Previous]" width="23" height="19" /></a></div><h2>Before</h2><h3><a href="/archive/NCT00504075/2009_07_17">(Updated 2009_07_17)</a></h3></th><th class="sdiff-b"><div class="sdiff-next"><a href="/archive/NCT00504075/2010_01_25/changes" title="Show changes from this version to next one"><img src="/archive/next.gif" alt="[Next]" width="23" height="19" /></a></div><h2>After</h2><h3><a href="/archive/NCT00504075/2009_10_02">(Updated 2009_10_02)</a></h3></th></tr>
<tr class="sdiff-unc" id="sdiff-chunk-m1"><td class="sdiff-h">1</td>
<td class="sdiff-a"><img id="sdiff-collapse-m0A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><img id="sdiff-collapse-m0A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-m0A-cdiv" class="sdiff-collapsed" title="The middle 69 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none"></div><div id="sdiff-collapse-m0A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  BioProducts</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  Bio Products Laboratory</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  GMX02</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT00504075</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;is_fda_regulated&gt;</div>
<div class="sdl2">  Yes</div>
<div class="sdl1 sdz">&lt;/is_fda_regulated&gt;</div>
<div class="sdl1 sds">&lt;is_section_801&gt;</div>
<div class="sdl2">  Yes</div>
<div class="sdl1 sdz">&lt;/is_section_801&gt;</div>
<div class="sdl1 sds">&lt;delayed_posting&gt;</div>
<div class="sdl2">  No</div>
<div class="sdl1 sdz">&lt;/delayed_posting&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  A Study to Find How Safe and Effective GAMMAPLEX&amp;#174; is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  A Phase III, Multicenter, Open-Label Study To Evaluate the Efficacy and Safety of GAMMAPLEX&amp;#174; in Chronic Idiopathic Thrombocytopenic Purpura</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Bio Products Laboratory</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;resp_party&gt;</div>
<div class="sdl2 sds">&lt;name_title&gt;</div>
<div class="sdl3">  James B Bussel, Principal Investigator</div>
<div class="sdl2 sdz">&lt;/name_title&gt;</div>
<div class="sdl2 sds">&lt;organization&gt;</div>
<div class="sdl3">  New York Presbyterian Hospital</div>
<div class="sdl2 sdz">&lt;/organization&gt;</div>
<div class="sdl1 sdz">&lt;/resp_party&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Food and Drug Administration</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl2 sds">&lt;has_dmc&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/has_dmc&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  The primary objective is to determine if BPL&amp;apos;s GAMMAPLEX raises the platelet count of subjects with chronic ITP to a threshold of 50 x 109/L, similar to that of a historical control.  The secondary objectives are:  1) to determine the safety of GAMMAPLEX at the dosage used in this study.  2) to determine if GAMMAPLEX maintains platelet counts of &amp;#179; 50 x 109/L in subjects with chronic ITP for a period of time similar to that of a historical control.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m0B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><img id="sdiff-collapse-m0B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-m0B-cdiv" class="sdiff-collapsed" title="The middle 69 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none"></div><div id="sdiff-collapse-m0B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  BioProducts</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  Bio Products Laboratory</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  GMX02</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT00504075</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;is_fda_regulated&gt;</div>
<div class="sdl2">  Yes</div>
<div class="sdl1 sdz">&lt;/is_fda_regulated&gt;</div>
<div class="sdl1 sds">&lt;is_section_801&gt;</div>
<div class="sdl2">  Yes</div>
<div class="sdl1 sdz">&lt;/is_section_801&gt;</div>
<div class="sdl1 sds">&lt;delayed_posting&gt;</div>
<div class="sdl2">  No</div>
<div class="sdl1 sdz">&lt;/delayed_posting&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  A Study to Find How Safe and Effective GAMMAPLEX&amp;#174; is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  A Phase III, Multicenter, Open-Label Study To Evaluate the Efficacy and Safety of GAMMAPLEX&amp;#174; in Chronic Idiopathic Thrombocytopenic Purpura</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Bio Products Laboratory</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;resp_party&gt;</div>
<div class="sdl2 sds">&lt;name_title&gt;</div>
<div class="sdl3">  James B Bussel, Principal Investigator</div>
<div class="sdl2 sdz">&lt;/name_title&gt;</div>
<div class="sdl2 sds">&lt;organization&gt;</div>
<div class="sdl3">  New York Presbyterian Hospital</div>
<div class="sdl2 sdz">&lt;/organization&gt;</div>
<div class="sdl1 sdz">&lt;/resp_party&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Food and Drug Administration</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl2 sds">&lt;has_dmc&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/has_dmc&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  The primary objective is to determine if BPL&amp;apos;s GAMMAPLEX raises the platelet count of subjects with chronic ITP to a threshold of 50 x 109/L, similar to that of a historical control.  The secondary objectives are:  1) to determine the safety of GAMMAPLEX at the dosage used in this study.  2) to determine if GAMMAPLEX maintains platelet counts of &amp;#179; 50 x 109/L in subjects with chronic ITP for a period of time similar to that of a historical control.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-m2"><td class="sdiff-h">2</td>
<td class="sdiff-a"><div class="sdl3"><span class="sdwc">2009-07</span> </div>
</td>
<td class="sdiff-b"><div class="sdl3"><span class="sdwc">2009-10</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m3"><td class="sdiff-h">3</td>
<td class="sdiff-a"><img id="sdiff-collapse-m72A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m72&#39;)" style="display:none" /><img id="sdiff-collapse-m72A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m72&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-m72A-cdiv" class="sdiff-collapsed" title="The middle 212 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m72&#39;)" style="display:none"></div><div id="sdiff-collapse-m72A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2007-08</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sda">&lt;last_follow_up_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2010-05</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sda">&lt;primary_compl_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2010-05</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/primary_compl_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 3</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Non-Randomized</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Open Label</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Historical Control</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Single Group Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Safety/Efficacy Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;number_of_arms&gt;</div>
<div class="sdl2">  1</div>
<div class="sdl1 sdz">&lt;/number_of_arms&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  The primary objective is to determine if BPL&amp;apos;s GAMMAPLEX raises the platelet count of subjects with chronic ITP to a threshold of 50 x 109/L, similar to that of a historical control.</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  3 to 6  months</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  To determine the safety of GAMMAPLEX at the dosage used in this study and to determine if GAMMAPLEX maintains platelet counts of &amp;#179; 50 x 109/L in subjects with chronic ITP for a period of time similar to that of a historical control.</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  3 to 6 months</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sda">&lt;enrollment</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2">  31</div>
<div class="sdl1 sdz">&lt;/enrollment&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Chronic Idiopathic Thrombocytopenic Purpura</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Biological/Vaccine</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Gammaplex, intravenous immunoglobulin</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  The first course of GAMMAPLEX will be administered as an intravenous infusion of 1 g/kg on each of 2 consecutive days.  If required, a further 1 or 2 courses on the same dosage regimen may be administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Gammaplex</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Biological/Vaccine</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Gammaplex</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Gammaplex&amp;#174; contains 5 g/100 mL of human normal immunoglobulin         (i.e. 50 g/L, of which virtually 100% is IgG).  The first course of GAMMAPLEX will be administered as an intravenous infusion of 1 g/kg on each of 2 consecutive days.  If required, a further 1 or 2 courses on the same dosage regimen may be administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  N/app</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Biological/Vaccine</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Gammaplex</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Dosage form: Gammaplex&amp;#174; is a sterile liquid of 5 % w/v normal immunoglobulin.  Gammaplex&amp;#174; contains 5 g/100 mL of human normal immunoglobulin (i.e. 50 g/L, of which virtually 100% is IgG). The first course of GAMMAPLEX will be administered as an intravenous infusion of 1 g/kg on each of 2 consecutive days.  If required, a further 1 or 2 courses on the same dosage regimen may be administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Gammaplex</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria:</div>
<div class="sdl4">  1) Males and females aged between 6 and 70 years.  </div>
<div class="sdl4">  2) Confirmed diagnosis of chronic ITP of at least 6 months duration.</div>
<div class="sdl4">  3) Platelet count of less than or equal to 20 x 10 9/L at enrollment.  </div>
<div class="sdl4">  4) Absence of other conditions that, in the opinion of the investigator, could cause thrombocytopenia.  </div>
<div class="sdl4">  5) If subjects are currently being treated with corticosteroids the treatment regimen/dose must have been stable (for a minimum of 2 weeks before screening).  However, subjects must remain on a stable treatment regimen.  If there is any intent to alter the corticosteroid treatment regimen (e.g., tapering of corticosteroids) before Day 10, subjects may not be included in the study.  </div>
<div class="sdl4">  6) If subjects are currently being treated with cyclophosphamide, azathioprine or attenuated androgens, the treatment regimen and dose must have been stable for a minimum of 2 months before screening.  However, if there is any intent to alter the treatment regimen before Day 10, subjects may not be included in the study.  </div>
<div class="sdl4">  7) Splenectomized subjects and both Rh(D)+ and Rh(D)- subjects may be included.  </div>
<div class="sdl4">  8) The subject has signed an informed consent form (if at least 18 years old) or the subject&amp;apos;s parent or legal guardian has signed the informed consent form.  If appropriate, the subject has signed a child assent form.  </div>
<div class="sdl4">  9) If a subject is a female of child-bearing potential, she must have a negative result on a urine-based HCG pregnancy test.  </div>
<div class="sdl4">  10) If a subject is a female who is or becomes sexually active, she must practice contraception by using a method of proven reliability for the duration of the study. </div>
<div class="sdl4">  </div>
<div class="sdl4">  Exclusion Criteria:</div>
<div class="sdl4">  1) The subject has a history of any severe or anaphylactic reaction to blood or any blood-derived product, or any severe reaction to IGIV or any other IgG preparation.  </div>
<div class="sdl4">  2) The subject is known to be intolerant to any component of the investigational product.  </div>
<div class="sdl4">  3) The subject has received any live virus vaccine within the last 3 months.  </div>
<div class="sdl4">  4) The subject has received an IGIV preparation within 1 month prior to screening.  </div>
<div class="sdl4">  5) The subject is currently receiving, or has received, any investigational agent within the 1 month prior to screening.    </div>
<div class="sdl4">  6) The subject has received any blood, blood product, or blood derivative within the 1 month prior to screening.  </div>
<div class="sdl4">  7) The subject has received Rituximab within the 3 months before screening</div>
<div class="sdl4">  8) The subject is pregnant or is nursing.  </div>
<div class="sdl4">  9) The subject is positive for any of the following at screening: HBsAg, NAT for HCV, NAT for HIV, Antibodies to HCV or HIV 1 or 2. </div>
<div class="sdl4">  10) The subject, at screening, has levels greater than 2.5 times the upper limit of normal, as defined by the central laboratory, of alanine aminotransferase or aspartate aminotransferase.  </div>
<div class="sdl4">  11) The subject has a severe renal impairment (defined as serum creatinine greater than 2 times the upper limit of normal or BUN greater than 2.5 times the upper limit of normal for the range of the laboratory doing the analysis); the subject is on dialysis; the subject has a history of acute renal failure.</div>
<div class="sdl4">  12) The subject is known to have abused alcohol, opiates, psychotropic agents, or other chemicals or drugs within the past 12 months.  </div>
<div class="sdl4">  13) The subject has a history of deep vein thrombosis (DVT) or thrombotic complications of IGIV therapy.  </div>
<div class="sdl4">  14) The subject has any history or sign of hyperviscosity, transient ischemic attack (TIA), stroke, other thromboembolic event, or unstable angina.  </div>
<div class="sdl4">  15) The subject suffers from any acute or chronic medical conditions (e.g., renal disease or predisposing conditions for renal disease, coronary artery disease, or protein losing enteropathy) that, in the opinion of the investigator, may interfere with the conduct of the study.  </div>
<div class="sdl4">  16) The subject has an acquired medical condition, such as chronic lymphocytic leukemia, lymphoma, multiple myeloma, chronic or recurrent neutropenia (defined as an absolute neutrophil count (ANC) &amp;lt; 1 x 109/L).  </div>
<div class="sdl4">  17) The subject has non-controlled arterial hypertension (systolic blood pressure &amp;gt;160 mmHg and/or diastolic blood pressure &amp;gt;90 mmHg).  </div>
<div class="sdl4">  18) The subject is anemic (hemoglobin &amp;lt;10 g/dL) at screening.  </div>
<div class="sdl4">  19) The subject is unlikely to adhere to the protocol requirements of the study or is likely to be uncooperative..</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  6 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl3">  70 Years</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Principal Investigator</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  James B Bussel, MD</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  New York Presbyterian Hospital</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;see_also&gt;</div>
<div class="sdl2 sds">&lt;annotation&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Sponsor website</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/annotation&gt;</div>
<div class="sdl2 sds">&lt;url&gt;</div>
<div class="sdl3">  http://www.bpl.co.uk</div>
<div class="sdl2 sdz">&lt;/url&gt;</div>
<div class="sdl1 sdz">&lt;/see_also&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Idiopathic Thrombocytopenic Purpura</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Bleeding disorders</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Immune System and Disorders</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2007-07-18</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
</div><div class="sdl1 sds">&lt;last_release_date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m72B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m72&#39;)" style="display:none" /><img id="sdiff-collapse-m72B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m72&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-m72B-cdiv" class="sdiff-collapsed" title="The middle 212 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m72&#39;)" style="display:none"></div><div id="sdiff-collapse-m72B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2007-08</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sda">&lt;last_follow_up_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2010-05</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sda">&lt;primary_compl_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2 sds">&lt;date&gt;</div>
<div class="sdl3">  2010-05</div>
<div class="sdl2 sdz">&lt;/date&gt;</div>
<div class="sdl1 sdz">&lt;/primary_compl_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  Phase 3</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Non-Randomized</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Open Label</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Historical Control</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Single Group Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Safety/Efficacy Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;number_of_arms&gt;</div>
<div class="sdl2">  1</div>
<div class="sdl1 sdz">&lt;/number_of_arms&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  The primary objective is to determine if BPL&amp;apos;s GAMMAPLEX raises the platelet count of subjects with chronic ITP to a threshold of 50 x 109/L, similar to that of a historical control.</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  3 to 6  months</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  To determine the safety of GAMMAPLEX at the dosage used in this study and to determine if GAMMAPLEX maintains platelet counts of &amp;#179; 50 x 109/L in subjects with chronic ITP for a period of time similar to that of a historical control.</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  3 to 6 months</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sda">&lt;enrollment</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2">  31</div>
<div class="sdl1 sdz">&lt;/enrollment&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Chronic Idiopathic Thrombocytopenic Purpura</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Biological/Vaccine</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Gammaplex, intravenous immunoglobulin</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  The first course of GAMMAPLEX will be administered as an intravenous infusion of 1 g/kg on each of 2 consecutive days.  If required, a further 1 or 2 courses on the same dosage regimen may be administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Gammaplex</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Biological/Vaccine</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Gammaplex</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Gammaplex&amp;#174; contains 5 g/100 mL of human normal immunoglobulin         (i.e. 50 g/L, of which virtually 100% is IgG).  The first course of GAMMAPLEX will be administered as an intravenous infusion of 1 g/kg on each of 2 consecutive days.  If required, a further 1 or 2 courses on the same dosage regimen may be administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  N/app</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Biological/Vaccine</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Gammaplex</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Dosage form: Gammaplex&amp;#174; is a sterile liquid of 5 % w/v normal immunoglobulin.  Gammaplex&amp;#174; contains 5 g/100 mL of human normal immunoglobulin (i.e. 50 g/L, of which virtually 100% is IgG). The first course of GAMMAPLEX will be administered as an intravenous infusion of 1 g/kg on each of 2 consecutive days.  If required, a further 1 or 2 courses on the same dosage regimen may be administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Gammaplex</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria:</div>
<div class="sdl4">  1) Males and females aged between 6 and 70 years.  </div>
<div class="sdl4">  2) Confirmed diagnosis of chronic ITP of at least 6 months duration.</div>
<div class="sdl4">  3) Platelet count of less than or equal to 20 x 10 9/L at enrollment.  </div>
<div class="sdl4">  4) Absence of other conditions that, in the opinion of the investigator, could cause thrombocytopenia.  </div>
<div class="sdl4">  5) If subjects are currently being treated with corticosteroids the treatment regimen/dose must have been stable (for a minimum of 2 weeks before screening).  However, subjects must remain on a stable treatment regimen.  If there is any intent to alter the corticosteroid treatment regimen (e.g., tapering of corticosteroids) before Day 10, subjects may not be included in the study.  </div>
<div class="sdl4">  6) If subjects are currently being treated with cyclophosphamide, azathioprine or attenuated androgens, the treatment regimen and dose must have been stable for a minimum of 2 months before screening.  However, if there is any intent to alter the treatment regimen before Day 10, subjects may not be included in the study.  </div>
<div class="sdl4">  7) Splenectomized subjects and both Rh(D)+ and Rh(D)- subjects may be included.  </div>
<div class="sdl4">  8) The subject has signed an informed consent form (if at least 18 years old) or the subject&amp;apos;s parent or legal guardian has signed the informed consent form.  If appropriate, the subject has signed a child assent form.  </div>
<div class="sdl4">  9) If a subject is a female of child-bearing potential, she must have a negative result on a urine-based HCG pregnancy test.  </div>
<div class="sdl4">  10) If a subject is a female who is or becomes sexually active, she must practice contraception by using a method of proven reliability for the duration of the study. </div>
<div class="sdl4">  </div>
<div class="sdl4">  Exclusion Criteria:</div>
<div class="sdl4">  1) The subject has a history of any severe or anaphylactic reaction to blood or any blood-derived product, or any severe reaction to IGIV or any other IgG preparation.  </div>
<div class="sdl4">  2) The subject is known to be intolerant to any component of the investigational product.  </div>
<div class="sdl4">  3) The subject has received any live virus vaccine within the last 3 months.  </div>
<div class="sdl4">  4) The subject has received an IGIV preparation within 1 month prior to screening.  </div>
<div class="sdl4">  5) The subject is currently receiving, or has received, any investigational agent within the 1 month prior to screening.    </div>
<div class="sdl4">  6) The subject has received any blood, blood product, or blood derivative within the 1 month prior to screening.  </div>
<div class="sdl4">  7) The subject has received Rituximab within the 3 months before screening</div>
<div class="sdl4">  8) The subject is pregnant or is nursing.  </div>
<div class="sdl4">  9) The subject is positive for any of the following at screening: HBsAg, NAT for HCV, NAT for HIV, Antibodies to HCV or HIV 1 or 2. </div>
<div class="sdl4">  10) The subject, at screening, has levels greater than 2.5 times the upper limit of normal, as defined by the central laboratory, of alanine aminotransferase or aspartate aminotransferase.  </div>
<div class="sdl4">  11) The subject has a severe renal impairment (defined as serum creatinine greater than 2 times the upper limit of normal or BUN greater than 2.5 times the upper limit of normal for the range of the laboratory doing the analysis); the subject is on dialysis; the subject has a history of acute renal failure.</div>
<div class="sdl4">  12) The subject is known to have abused alcohol, opiates, psychotropic agents, or other chemicals or drugs within the past 12 months.  </div>
<div class="sdl4">  13) The subject has a history of deep vein thrombosis (DVT) or thrombotic complications of IGIV therapy.  </div>
<div class="sdl4">  14) The subject has any history or sign of hyperviscosity, transient ischemic attack (TIA), stroke, other thromboembolic event, or unstable angina.  </div>
<div class="sdl4">  15) The subject suffers from any acute or chronic medical conditions (e.g., renal disease or predisposing conditions for renal disease, coronary artery disease, or protein losing enteropathy) that, in the opinion of the investigator, may interfere with the conduct of the study.  </div>
<div class="sdl4">  16) The subject has an acquired medical condition, such as chronic lymphocytic leukemia, lymphoma, multiple myeloma, chronic or recurrent neutropenia (defined as an absolute neutrophil count (ANC) &amp;lt; 1 x 109/L).  </div>
<div class="sdl4">  17) The subject has non-controlled arterial hypertension (systolic blood pressure &amp;gt;160 mmHg and/or diastolic blood pressure &amp;gt;90 mmHg).  </div>
<div class="sdl4">  18) The subject is anemic (hemoglobin &amp;lt;10 g/dL) at screening.  </div>
<div class="sdl4">  19) The subject is unlikely to adhere to the protocol requirements of the study or is likely to be uncooperative..</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  6 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl3">  70 Years</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Principal Investigator</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  James B Bussel, MD</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  New York Presbyterian Hospital</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;see_also&gt;</div>
<div class="sdl2 sds">&lt;annotation&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Sponsor website</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/annotation&gt;</div>
<div class="sdl2 sds">&lt;url&gt;</div>
<div class="sdl3">  http://www.bpl.co.uk</div>
<div class="sdl2 sdz">&lt;/url&gt;</div>
<div class="sdl1 sdz">&lt;/see_also&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Idiopathic Thrombocytopenic Purpura</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Bleeding disorders</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Immune System and Disorders</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2007-07-18</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
</div><div class="sdl1 sds">&lt;last_release_date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-m4"><td class="sdiff-h">4</td>
<td class="sdiff-a"><div class="sdl2"><span class="sdwc">2009-07-17</span> </div>
</td>
<td class="sdiff-b"><div class="sdl2"><span class="sdwc">2009-10-02</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m5"><td class="sdiff-h">5</td>
<td class="sdiff-a"><img id="sdiff-collapse-m287A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m287&#39;)" style="display:none" /><img id="sdiff-collapse-m287A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m287&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
<div id="sdiff-collapse-m287A-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m287&#39;)" style="display:none"></div><div id="sdiff-collapse-m287A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;init_disposition_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_disposition_release_date&gt;</div>
<div class="sdl1 sds">&lt;init_results_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_results_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m287B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m287&#39;)" style="display:none" /><img id="sdiff-collapse-m287B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m287&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
<div id="sdiff-collapse-m287B-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m287&#39;)" style="display:none"></div><div id="sdiff-collapse-m287B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;init_disposition_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_disposition_release_date&gt;</div>
<div class="sdl1 sds">&lt;init_results_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_results_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
</tr>

</table></div></form><div class="navBottom"><div class="navBottomLine" style="background-image: url(/archive/ctgov_logo_ttm.gif)">&#160;</div><div class="navBottomLinks">&#160;</div></div><script>
SDiffDeclareUnchCRID('sdiff-collapse-f0');
SDiffDeclareUnchCRID('sdiff-collapse-f356');
SDiffDeclareUnchCRID('sdiff-collapse-f375');
SDiffDeclareUnchCRID('sdiff-collapse-f465');
SDiffDeclareUnchCRID('sdiff-collapse-f578');
SDiffDeclareUnchCRID('sdiff-collapse-f602');
SDiffDeclareUnchCRID('sdiff-collapse-f72');
SDiffDeclareUnchCRID('sdiff-collapse-m0');
SDiffDeclareUnchCRID('sdiff-collapse-m287');
SDiffDeclareUnchCRID('sdiff-collapse-m72');
SDiffInit();
</script></body></html>